Bosutinib instructions details and how to take it

Bosutinib is an oral small molecule tyrosine kinase inhibitor (TKI), mainly used to treat Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). As a second-generation TKI, bosutinib provides an important treatment option for patients who are resistant or intolerant to imatinib (Imatinib). This article will comprehensively introduce the instructions for bosutinib from various aspects such as basic drug information, indications, usage and dosage, adverse reactions, precautions, and medication methods to help patients use this drug scientifically and safely.

1. Basic information about drugs

Common name: Bosutinib (Bosutinib)

Commodity name:Bosulif (a common brand name abroad)

Drug category: second generationBCR-ABLTyrosine kinase inhibitor

Dosage form specifications: Common specifications are 100 mg, 400 mg, 500 mgoral tablets

Approval number: The National Food and Drug Administration of China (NMPA) has approved the import of bosutinib as a prescription drug for the treatment of Ph+ CMLpatients

2. Indications

Bosutinib is mainly used for the following eligible groups:

1.Adult patients with chronic myelogenous leukemia (CML) in newly treated chronic phasePh+

2.As a first-line treatment drug, it is one of the targeted treatment options for initial treatment of CML along with imatinib and dasatinib.

3.Patients with drug-resistant or intolerant Ph+ CML

4.Can be used for patients in chronic phase, accelerated phase or blast phaseCML, especially for those who cannot continue prodrug treatment due to drug resistance mutations or adverse reactions.

3. Usage and dosage

Bosutinib should be administered on an individualized basis under the guidance of a doctor. Commonly recommended uses are as follows:

1.Initial treatmentCMLChronic phase patients

The recommended dose is 400 mg orally once daily. Swallow the tablet whole with water and take it with food to improve drug absorption and reduce gastrointestinal irritation.

2.Patients with CML who have failed or are intolerant to previous treatment

The recommended dose is 500 mg once dailyorally. It should also be taken with food.

3.Dose adjustment

If the patient experiences adverse reactions, such as elevated liver enzymes, diarrhea, bone marrow suppression, etc., temporary drug discontinuation or dose reduction to 300 mg or even a lower dose may be considered. After recovery, the dose can be gradually increased according to tolerance.

4.Handling of missed doses

If you miss a dose, you should take it as soon as possible; but if it is close to the next dose time, just skip the missed dose, and you should not take a double dose at one time.

4. Common adverse reactions

Although bosutinib has good target selectivity, it may still cause some adverse reactions. Patients need to pay close attention and report to their doctor in time:

1.Gastrointestinal reactions

The most common symptoms are diarrhea, nausea, vomiting, abdominal pain, etc., which often appear in the early stages of medication. It is usually mild to moderate and may resolve over a few days to a few weeks.

It is recommended to eat a light diet during the medication and take antidiarrheal drugs (such as loperamide) for symptomatic relief.

2.Abnormal liver function

ALT, ASTThe increase is a common laboratory test abnormality, and liver function needs to be monitored regularly. If there is a significant increase, the medication can be suspended.

3.Influence on blood system

Leukopenia, neutropenia, and thrombocytopenia are common manifestations of bone marrow suppression, and routine blood examinations need to be performed regularly.

4.Other discomforts

These include fatigue, rashes, headaches, weight loss, muscle pain, increased risk of infection, and more.

5. Precautions and medication contraindications

1.Pre-medication assessment

Before taking medicine, basic examinations such as liver and kidney function, blood routine, and electrocardiogram should be carried out to determine whether there are serious complications or drug contraindications.

2. Liver and kidney dysfunction

For patients with mild to moderate hepatic impairment, a lower starting dose should be considered; patients with severe liver disease should use it with caution.

3.Contraindicated for pregnant and lactating women

Bosutinib may have adverse effects on the fetus and is contraindicated during pregnancy or planned pregnancy; use during lactation should also be avoided.

4.Drug interactions

Bosutinib is mainly metabolized by the liverCYP3A4 and should be avoided in combination with CYP3A4 strong inhibitors or inducers (such as ketoconazole, rifampicin).

Simultaneous use of antacids (such as proton pump inhibitors) may reduce the efficacy of the drug, and it is necessary to take it 2 hours apart or adjust the regimen.

6. Medication suggestions and management points

1. How to take the medicine: Swallow the tablet whole at regular times every day with meals. Do not break or chew it. Avoid taking it with grapefruit-like foods.

2.Monitoring indicators: including blood routine, liver function, electrolytes (potassium, magnesium), electrocardiogram (QT interval), etc., should be reviewed regularly.

3.Patient education: inform about possible adverse reactions, how to deal with missed doses, when to seek medical treatment, etc., to improve compliance.

4.Long-term management: The BCR-ABL fusion gene level should be evaluated during treatment to monitor the efficacy and determine whether the regimen needs to be changed.

7. Conclusion

Bosutinib is an important targeted therapy drug that provides a new treatment option for patients with Ph+chronic myelogenous leukemia, especially those who are resistant or intolerant to first-line TKI. During the medication process, it is necessary to strictly follow the dosage instructions and doctor's recommendations, and at the same time closely monitor related side effects and laboratory indicators. Proper medication use, scientific management, and early intervention can maximize drug efficacy, reduce risks, and improve patients' treatment compliance and quality of life.

Reference materials:https://www.drugs.com/